Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor
L Gan, T Langenickel, J Petruck, K Kode… - The Journal of …, 2016 - Wiley Online Library
LCZ696, a novel angiotensin receptor neprilysin inhibitor, is in development for the
treatment of heart failure. Administration of LCZ696 results in systemic exposure to sacubitril …
treatment of heart failure. Administration of LCZ696 results in systemic exposure to sacubitril …
Pharmacokinetics, safety and tolerability of sacubitril/valsartan (LCZ696) after single-dose administration in healthy chinese subjects
Y Han, S Ayalasomayajula, W Pan, F Yang… - European journal of …, 2017 - Springer
Abstract Background and Objective Sacubitril/valsartan (LCZ696) is a first-in-class
angiotensin receptor neprilysin inhibitor (ARNI) and has been recently approved in several …
angiotensin receptor neprilysin inhibitor (ARNI) and has been recently approved in several …
Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol
H Hsiao, TH Langenickel, M Greeley… - Clinical …, 2015 - Wiley Online Library
LCZ696 is a first‐in‐class angiotensin receptor neprilysin inhibitor in development for
treatments of hypertension and heart failure indications. In 3 separate studies …
treatments of hypertension and heart failure indications. In 3 separate studies …
Pharmacokinetic drug–drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel‐ethinyl …
L Gan, X Jiang, A Mendonza, T Swan… - Clinical …, 2016 - Wiley Online Library
LCZ696 is a novel angiotensin receptor neprilysin inhibitor in development for the treatment
of cardiovascular diseases. Here, we assessed the potential for pharmacokinetic drug‐drug …
of cardiovascular diseases. Here, we assessed the potential for pharmacokinetic drug‐drug …
Pharmacokinetics after single ascending dose, food effect, and safety of sacubitril/valsartan (LCZ696), an angiotensin receptor and neprilysin inhibitor, in healthy …
M Akahori, S Ayalasomayajula, T Langenickel… - European Journal of …, 2017 - Springer
Background and Objectives LCZ696 (sacubitril/valsartan) is a novel angiotensin receptor
neprilysin inhibitor (ARNI) that has been developed for treatment of heart failure patients …
neprilysin inhibitor (ARNI) that has been developed for treatment of heart failure patients …
Effect of food on the oral bioavailability of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
S Ayalasomayajula, T Langenickel… - … Journal of Clinical …, 2016 - search.proquest.com
Objective: Sacubitril/valsartan (LCZ696) provides a novel therapeutic approach of
neurohormonal modulation in heart failure via simultaneous inhibition of neprilysin and …
neurohormonal modulation in heart failure via simultaneous inhibition of neprilysin and …
[PDF][PDF] Mizuki Akahori, Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Wei Zhou & Gangadhar Sunkara
PAS Ascending - researchgate.net
Background and Objectives LCZ696 (sacubitril/valsartan) is a novel angiotensin receptor
neprilysin inhibitor (ARNI) that has been developed for treatment of heart failure patients …
neprilysin inhibitor (ARNI) that has been developed for treatment of heart failure patients …